Joshua Price

Dr. Joshua Price

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
MCMartina Colicchia
Martina Colicchia
WSWaltraud C. Schrottmaier
Waltraud C. Schrottmaier
GPGina Perrella
Gina Perrella
JRJasmeet S. Reyat
Jasmeet S. Reyat
JBJenefa Begum
Jenefa Begum
JRJulie Rayes
Julie Rayes
S100A8/A9, also known as “calprotectin” or “MRP8/14,” is an alarmin primarily secreted by activated myeloid cells with antimicrobial, proinflammatory, and prothrombotic properties. Increased plasma levels of S100A8/A9 in thrombo-inflammatory diseases are associated with thrombotic complications. We assessed the presence of S100A8/A9 in the plasma and lung autopsies from patients with COVID-19 and investigated the molecular mechanism by which S100A8/A9 affects platelet function and thrombosis. S100A8/A9 plasma levels were increased in patients with COVID-19 and sustained high levels during hospitalization correlated with poor outcomes. Heterodimeric S100A8/A9 was mainly detected in neutrophils and deposited on the vessel wall in COVID-19 lung autopsies. Immobilization of S100A8/A9 with collagen accelerated the formation of a fibrin-rich network after perfusion of recalcified blood at venous shear. In vitro, platelets adhered and partially spread on S100A8/A9, leading to the formation of distinct populations of either P-selectin or phosphatidylserine (PS)-positive platelets. By using washed platelets, soluble S100A8/A9 induced PS exposure but failed to induce platelet aggregation, despite GPIIb/IIIa activation and alpha-granule secretion. We identified GPIbα as the receptor for S100A8/A9 on platelets inducing the formation of procoagulant platelets with a supporting role for CD36. The effect of S100A8/A9 on platelets was abolished by recombinant GPIbα ectodomain, platelets from a patient with Bernard-Soulier syndrome with GPIb-IX-V deficiency, and platelets from mice deficient in the extracellular domain of GPIbα. We identified the S100A8/A9-GPIbα axis as a novel targetable prothrombotic pathway inducing procoagulant platelets and fibrin formation, in particular in diseases associated with high levels of S100A8/A9, such as COVID-19.


6 June 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
CDCaitlin Ditchfield
Caitlin Ditchfield
Joshua PriceJoshua Price
Joshua Price
EDEdward T Davis
Edward T Davis
SJSimon W Jones
Simon W Jones
Synovial inflammation is recognised as a pathological driver of osteoarthritis (OA), a degenerative joint disease involving cartilage degradation and joint pain. Since extracellular vesicles (EVs) have emerged as key mediators of cellular cross-talk, this study characterised synovial fluid EVs (SFEVs) in OA patients with varying disease severity and determined their functional effects on OA articular chondrocytes. Synovial fluid and articular cartilage were collected from patients undergoing knee surgery. SFEVs were isolated via ultracentrifugation and characterised by nanoparticle tracking analysis, ExoView, and Luminex analysis of protein cargo. Patients were stratified into mild/moderate- and severe-OA groups based on Oxford Knee Score and EQ5D. Chondrocytes were treated with SFEVs, and transcriptomic and secretome responses were analysed using RNA sequencing, Luminex, and ELISA. SFEVs from patients with severe OA were more abundant, smaller and exhibited increased tetraspanin expression. Synovial fluid and SFEVs induced distinct transcriptomic changes in chondrocytes. SFEVs from patients with severe OA promoted a pro-inflammatory and catabolic chondrocyte phenotype, with upregulation of CRTAC1, COL6A3, TNC, and CXCL5, greater secretion of IL-6, MMP1, MMP3 and MMP13, and pro-nociceptive mediators (NGF and Substance P). These findings suggest that SFEVs may contribute to OA progression by exacerbating cartilage damage and promoting pain sensitisation.

3 February 2026 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
Joshua PriceJoshua Price
Joshua Price
MMMichael Macleod
Michael Macleod
TNThomas Nicholson
Thomas Nicholson
CDCaitlin M. Ditchfield
Caitlin M. Ditchfield
BABethy Airstone
Bethy Airstone
SJSimon W Jones
Simon W Jones
Background: Sarcopenic obesity, where excess body fat coexists with reduced muscle mass and function, is becoming increasingly common in ageing populations and contributes to poor physical and metabolic health. Although adipose tissue–secreted factors are implicated in muscle decline, the specific mechanisms remain unclear. Extracellular vesicles (EVs), which carry regulatory cargo such as microRNAs (miRNAs) between cells, may play a key role in this adipose–muscle communication. Methods: EVs were isolated from adipose‐conditioned media (ACM) collected from lean and non‐lean human donors using ultracentrifugation. Donors were grouped by BMI (lean: 20.7–24.4; non‐lean: 25.3–39.3) and age (younger: 31–56 years; older: 60–84 years). EVs were characterised using nanoparticle tracking analysis (NTA), ExoView, nanoscale flow cytometry (CytoFLEX Nano) and transmission electron microscopy (TEM). Primary human myoblasts were differentiated into myotubes and treated for 24 h with lean or non‐lean EVs (1.3 × 10 9 particles/mL) or left untreated. Myotube thickness was measured by immunofluorescence microscopy. Transcriptomic changes were assessed by bulk RNA sequencing. EV miRNA cargo was profiled by small RNA‐seq and validated by qPCR. The role of miR‐150‐5p was tested using antagomir inhibition. Results: Non‐lean EVs significantly reduced myotube thickness in older adult‐derived myotubes compared to both untreated controls (8.7 ± 1.66 μm vs. 12.4 ± 1.72 μm, p < 0.01) and lean EV‐treated myotubes (8.7 ± 1.66 μm vs. 13.2 ± 3.84 μm, p < 0.05), indicating a donor BMI‐specific effect. This atrophy was restricted to myotubes derived from older donors. The same experimental approach was applied to younger adult‐derived myotubes; no reduction in myotube thickness was observed. MAFbx expression was significantly increased in response to non‐lean EVs ( p < 0.05). RNA‐seq revealed 471 differentially expressed genes (DEGs) in EV‐treated versus untreated cells and 293 DEGs between lean and non‐lean EV conditions, with enrichment in inflammatory (TNF and IL1B), oxidative stress, mitochondrial and chromatin pathways. Small RNA‐seq identified seven differentially expressed miRNAs (annotated using miRBase release 22.1), including miR‐150‐5p and miR‐193b‐5p, both significantly upregulated in non‐lean EVs and validated by qPCR. Inhibiting miR‐150‐5p partially rescued myotube thickness (10.5 ± 1.37 μm vs. 8.7 ± 1.66 μm, p < 0.05) and reduced MAFbx expression. Conclusions: EVs from non‐lean adipose tissue drive muscle atrophy and transcriptional changes in an age‐dependent manner. These effects are partially mediated by miR‐150‐5p, highlighting a mechanistic role for EV cargo in adipose‐muscle signalling. Targeting EV‐derived miRNAs may offer a novel strategy to combat muscle loss in obesity and ageing.

25 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CDCaitlin Ditchfield
Caitlin Ditchfield
Joshua PriceJoshua Price
Joshua Price
EDEdward T Davis
Edward T Davis
SJSimon W Jones
Simon W Jones
Synovial inflammation is recognised as a pathological driver of osteoarthritis (OA), a degenerative joint disease involving cartilage degradation and joint pain. Since extracellular vesicles (EVs) have emerged as key mediators of cellular cross-talk, this study characterised synovial fluid EVs (SFEVs) in OA patients with varying disease severity, and determined their functional effects on OA articular chondrocytes. Synovial fluid and articular cartilage were collected from patients undergoing knee surgery. SFEVs were isolated via ultracentrifugation and characterised by nanoparticle tracking analysis, ExoView and Luminex analysis of protein cargo. Patients were stratified into mild/moderate and severe OA groups based on Oxford Knee Score and EQ5D. Chondrocytes were treated with SFEVs, and transcriptomic and secretome responses were analysed using RNA sequencing, Luminex, and ELISA. SFEVs from severe OA patients were more abundant, smaller and exhibited increased tetraspanin expression. Synovial fluid and SFEVs induced distinct transcriptomic changes in chondrocytes. SFEVs from severe OA patients promoted a pro-inflammatory and catabolic chondrocyte phenotype, with upregulation of CRTAC1, COL6A3, TNC, and CXCL5, and greater secretion of IL-6, MMP1, MMP3 and MMP13, and pro-nociceptive mediators (NGF and Substance P). These findings suggest that SFEVs may contribute to OA progression by exacerbating cartilage damage and promoting pain sensitisation.

11 December 2025 in bioRxiv
Verified
Preprint
Open access
Joshua PriceJoshua Price
Joshua Price
MMMicahel Macleod
Micahel Macleod
TNThomas Nicholson
Thomas Nicholson
CDCaitlin Ditchfield
Caitlin Ditchfield
BABethy Airstone
Bethy Airstone
SJSimon W Jones
Simon W Jones
Background: Sarcopenic obesity, where excess body fat coexists with reduced muscle mass and function, is becoming increasingly common in ageing populations and contributes to poor physical and metabolic health. Although adipose tissue-secreted factors are implicated in muscle decline, the specific mechanisms remain unclear. Extracellular vesicles (EVs), which carry regulatory cargo such as microRNAs (miRNAs) between cells, may play a key role in this adipose-muscle communication. Methods: EVs were isolated from adipose-conditioned media (ACM) collected from lean and non-lean human donors using ultracentrifugation. Donors were grouped by BMI (lean: 20.7-24.4; non-lean: 25.3-39.3) and age (younger: 31-56 years; older: 60-84 years). EVs were characterised using nanoparticle tracking analysis (NTA), ExoView, nanoscale flow cytometry (CytoFLEX Nano), and transmission electron microscopy (TEM). Primary human myoblasts were differentiated into myotubes and treated for 24 hours with lean or non-lean EVs (1.3x10^9 particles/ml) or left untreated. Myotube thickness was measured by immunofluorescence microscopy. Transcriptomic changes were assessed by bulk RNA sequencing. EV miRNA cargo was profiled by small RNA-seq and validated by qPCR. The role of miR-150-5p was tested using antagomir inhibition. Results: Non-lean EVs significantly reduced myotube thickness compared to both untreated controls (8.7 +/- 1.66 um vs. 12.4 +/- 1.72 um, p < 0.01) and lean EV-treated myotubes (8.7 +/- 1.66 um vs. 13.2 +/- 3.84 um, p < 0.05), indicating a donor BMI-specific effect. This atrophy was restricted to myotubes derived from older donors. MAFbx expression was significantly increased in response to non-lean EVs (p < 0.05). RNA-seq revealed 471 differentially expressed genes (DEGs) in EV-treated vs. untreated cells and 293 DEGs between lean and non-lean EV conditions, with enrichment in inflammatory (TNF, IL1B), oxidative stress, mitochondrial, and chromatin pathways. Small RNA-seq identified 7 differentially expressed miRNAs, including miR-150-5p and miR-193b-5p, both significantly upregulated in non-lean EVs and validated by qPCR. Inhibiting miR-150-5p partially rescued myotube thickness (10.5 +/- 1.37 um vs. 8.7 +/- 1.66 um, p < 0.05) and reduced MAFbx expression. Conclusions: EVs from non-lean adipose tissue drive muscle atrophy and transcriptional changes in an age-dependent manner. These effects are partially mediated by miR-150-5p, highlighting a mechanistic role for EV cargo in adipose-muscle signalling. Targeting EV-derived miRNAs may offer a novel strategy to combat muscle loss in obesity and ageing.